Acthar marketing drives prescriptions and anger

Share this article:

Questcor Pharmaceutical's marketing push for the injectable Acthar has simultaneously driven prescription rates and scorn.

ProPublica and the New York Times note that the drug is a curiosity of sorts: the biologic has been on the US market since 1952, when the FDA only required manufacturers to prove a drug is safe, not that it was effective. Since then the number of its approved uses has climbed to as many as 50 and has been pared back to as few as 19.

The safety-only approval criteria is what has payers taking note, since doctors have been prescribing the medication for multiple sclerosis even though there is little in the way of clinical trials showing that it is an effective treatment. It is, however, an expensive one, costing around $32,000 for each five-dose vial.

This seems small, considering the uproar surrounding Gilead's hepatitis C treatment Sovaldi, which clocks in at around $84,000, but as ProPublica and the Times note, Gilead has documented Sovaldi's hepatitis C impact, whereas Acthar is getting by on robust marketing support and supportive physicians.

The significance of this combination is clear by the numbers the two news groups have dug up, including that the drug's top prescriber, who also talks about the drug for Questcor, accounted for more than $4 million in Acthar prescriptions two years ago.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.